Kamangar F., Dores G.M., and Anderson W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24 14 (2006) 2137-2150
Hoeffel C., Mulé S., Romaniuk B., et al. Advances in radiological imaging of gastrointestinal tumors. Crit Rev Oncol Hematol (2008 Jul 30) [Epub ahead of print]
Veit P., Kühle C., Beyer T., et al. Whole body positron emission tomography/computed tomography (PET/CT) tumour staging with integrated PET/CT colonography: technical feasibility and first experiences in patients with colorectal cancer. Gut 55 1 (2006) 68-73
Scott A.M., Gunawardana D.H., Kelley B., et al. PET Changes Management and Improves Prognostic Stratification in Patients with Recurrent Colorectal Cancer: Results of a Multicenter Prospective Study. J Nucl Med 49 9 (2008) 1451-1457
Wiering B., Krabbe P.F., Dekker H.M., et al. The role of FDG-PET in the selection of patients with colorectal liver metastases. Ann Surg Oncol 14 2 (2007) 771-779
Chua S.C., Groves A.M., Kayani I., et al. The impact of 18F-FDG PET/CT in patients with liver metastases. Eur J Nucl Med Mol Imaging 34 12 (2007) 1906-1914
Kong G., Jackson C., Koh D.M., et al. The use of 18F-FDG PET/CT in colorectal liver metastases-comparison with CT and liver MRI. Eur J Nucl Med Mol Imaging 35 7 (2008) 1323-1329
Sobhani I., Tiret E., Lebtahi R., et al. Early detection of recurrence by 18FDG-PET in the follow-up of patients with colorectal cancer. Br J Cancer 98 5 (2008) 875-880
Davey K., Heriot A.G., Mackay J., et al. The impact of 18-fluorodeoxyglucose positron emission tomography-computed tomography on the staging and management of primary rectal cancer. Dis Colon Rectum 51 7 (2008) 997-1003
Meyers B.F., Downey R.J., Decker P.A., et al. The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial. J Thorac Cardiovasc Surg 133 3 (2007) 738-745
Lordick F., Ott K., Krause B.J., et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 8 9 (2007) 797-805
Wieder H.A., Brücher B.L., Zimmermann F., et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 22 5 (2004) 900-908
Ott K., Herrmann K., Lordick F., et al. Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res 14 7 (2008) 2012-2018
Pakzad F., Groves A.M., and Ell P.J. The role of positron emission tomography in the management of pancreatic cancer. Semin Nucl Med 36 3 (2006) 248-256
Rose D.M., Delbeke D., Beauchamp R.D., et al. 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Ann Surg 229 5 (1999) 729-737 discussion 737-8
Ruf J., Lopez Hänninen E., Oettle H., et al. Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI. Pancreatology 5 2-3 (2005) 266-272
Kalady M.F., Clary B.M., Clark L.A., et al. Clinical utility of positron emission tomography in the diagnosis and management of periampullary neoplasms. Ann Surg Oncol 9 8 (2002) 799-806
Yoon K.T., Kim J.K., Kim do Y., et al. Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma. Oncology 72 Suppl 1 (2007) 104-110
Ho C.L., Chen S., Yeung D.W., et al. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med 48 6 (2007) 902-909
Corvera C.U., Blumgart L.H., Akhurst T., et al. 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg 206 1 (2008) 57-65
Moon C.M., Bang S., Chung J.B., et al. Usefulness of 18F-fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas. J Gastroenterol Hepatol 23 5 (2008) 759-765
Pasquali C., Rubello D., Sperti C., et al. Neuroendocrine tumor imaging: can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior?. World J Surg 22 6 (1998) 588-592
Kowalski J., Henze M., Schuhmacher J., et al. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 5 1 (2003) 42-48
Ambrosini V., Tomassetti P., Castellucci P., et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging 35 8 (2008) 1431-1438
